Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma

CD30 and programmed cell death protein 1 (PD-1) are two ideal therapeutic targets in classical Hodgkin lymphoma (cHL). The CD30 antibody-drug conjugate (ADC) brentuximab vedotin and the PD-1 antibodies nivolumab and pembrolizumab are highly efficacious in treating relapsed and/or refractory cHL. Ong...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Hematol Oncol
Prif Awduron: Wang, Yucai, Nowakowski, Grzegorz S., Wang, Michael L., Ansell, Stephen M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2018
Pynciau:
Review
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5914042/
https://ncbi.nlm.nih.gov/pubmed/29685160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-018-0601-9
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg